Immunologic profile of human immunodeficiency virus-infected patients during viral remission and relapse on antiretroviral therapy.

A dissociation between plasma human immunodeficiency virus (HIV) RNA levels and CD4(+) cell counts has been reported in patients experiencing viral relapse while receiving antiretroviral therapy. This study compared patients with stable CD4(+) lymphocytes during viral relapse while receiving treatment with patients who had sustained virus suppression. Plasma HIV RNA levels, lymphocyte immunophenotyping, and T cell receptor excision circle (TREC) levels were measured. Naive CD4(+) lymphocyte phenotype and TREC levels were not significantly different in patients with virus suppression or in those who had relapsed. However, CD8(+) lymphocyte activation, including the number and percentage of activated cells and CD38 antibody-binding capacity, was significantly elevated during viral relapse, compared with that in suppressed patients. By multivariable regression analyses, CD8(+) and CD4(+) lymphocyte activation were associated significantly with increasing plasma HIV RNA levels.

[1]  R. Grant,et al.  Sustained CD4+ T cell response after virologic failure of protease inhibitor-based regimens in patients with human immunodeficiency virus infection. , 2000, The Journal of infectious diseases.

[2]  M. Lederman,et al.  Response to immunization with recall and neoantigens after prolonged administration of an HIV-1 protease inhibitor-containing regimen , 2000, AIDS.

[3]  B. Haynes,et al.  The role of the thymus in immune reconstitution in aging, bone marrow transplantation, and HIV-1 infection. , 2000, Annual review of immunology.

[4]  J V Giorgi,et al.  Shorter survival in advanced human immunodeficiency virus type 1 infection is more closely associated with T lymphocyte activation than with plasma virus burden or virus chemokine coreceptor usage. , 1999, The Journal of infectious diseases.

[5]  A. Telenti,et al.  Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study , 1999, The Lancet.

[6]  Gea-Banacloche Jc,et al.  Immune reconstitution in HIV infection. , 1999 .

[7]  J. Gea-Banacloche,et al.  Immune reconstitution in HIV infection. , 1999, AIDS.

[8]  Louis J. Picker,et al.  Changes in thymic function with age and during the treatment of HIV infection , 1998, Nature.

[9]  R. Detels,et al.  Immunologic effects of combined protease inhibitor and reverse transcriptase inhibitor therapy in previously treated chronic HIV‐1 infection , 1998, AIDS.

[10]  R. Detels,et al.  CD8+ T-lymphocyte activation in HIV-1 disease reflects an aspect of pathogenesis distinct from viral burden and immunodeficiency. , 1998, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

[11]  Rob J. De Boer,et al.  Biphasic kinetics of peripheral blood T cells after triple combination therapy in HIV-1 infection: A composite of redistribution and proliferation , 1998, Nature Medicine.

[12]  J Leibowitch,et al.  Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. , 1997, Science.

[13]  H. Schuitemaker,et al.  Viro‐immunological studies in acute HIV‐1 infection , 1994, AIDS.

[14]  R. Detels,et al.  T-cell subset alterations in HIV-infected homosexual men: NIAID Multicenter AIDS cohort study. , 1989, Clinical immunology and immunopathology.